Literature DB >> 15964334

Factors contributing to acute rejection in renal transplantation: the role of noncompliance.

P E Morrissey1, S Reinert, A Yango, A Gautam, A Monaco, R Gohh.   

Abstract

Early episodes of acute rejection after renal transplantation reflect inadequate immunosuppression at a time of heightened immune challenge. Late acute rejection episodes, however, are less likely related to inadequacy of immunosuppression and may be due to patient noncompliance or overzealous weaning of immunosuppression. We evaluated 443 consecutive renal transplant recipients to determine the incidence and etiology of acute rejection. All episodes were confirmed by ultrasound-guided biopsy. The cause of each acute rejection was determined by chart review. Medication compliance was determined by history at the time of admission for biopsy. Over a follow-up period of 42 +/- 22 months, 87 patients (20%) suffered acute rejection. There was a trend toward fewer episodes of acute rejection with thymoglobulin induction and tacrolimus-based immunosuppression. Younger recipients had an increased risk of acute rejection (odds ratio 0.47, range 0.24-0.91, P = .027). Patient noncompliance with immunosuppression was associated with late acute rejection (P = .0002). Acute rejection increased the risk of allograft failure (P < .0001). Modifiable factors, including the choice of immunosuppression, reduce the risk of acute rejection. More importantly, the transplant recipient plays a substantial role in the maintenance of their allograft health through compliance with immunosuppressive drug therapy. Future strategies to improve compliance, including increased vigilance in high-risk patient groups, frequent medication review, and laboratory testing, should be encouraged.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964334     DOI: 10.1016/j.transproceed.2005.03.017

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  14 in total

1.  Associations of pre-transplant prescription narcotic use with clinical complications after kidney transplantation.

Authors:  Krista L Lentine; Ngan N Lam; Huiling Xiao; Janet E Tuttle-Newhall; David Axelrod; Daniel C Brennan; Vikas R Dharnidharka; Hui Yuan; Mustafa Nazzal; Jie Zheng; Mark A Schnitzler
Journal:  Am J Nephrol       Date:  2015-03-27       Impact factor: 3.754

2.  Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling.

Authors:  S M Kurian; A N Williams; T Gelbart; D Campbell; T S Mondala; S R Head; S Horvath; L Gaber; R Thompson; T Whisenant; W Lin; P Langfelder; E H Robison; R L Schaffer; J S Fisher; J Friedewald; S M Flechner; L K Chan; A C Wiseman; H Shidban; R Mendez; R Heilman; M M Abecassis; C L Marsh; D R Salomon
Journal:  Am J Transplant       Date:  2014-04-11       Impact factor: 8.086

3.  Medication adherence in the transition of adolescent kidney transplant recipients to the adult care.

Authors:  Oleh M Akchurin; Michal L Melamed; Becky L Hashim; Frederick J Kaskel; Marcela Del Rio
Journal:  Pediatr Transplant       Date:  2014-05-13

Review 4.  Medication noncompliance and its implications in transplant recipients.

Authors:  Paul E Morrissey; Michelle L Flynn; Sonia Lin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.

Authors:  S Bunnapradist; K Ciechanowski; P West-Thielke; S Mulgaonkar; L Rostaing; B Vasudev; K Budde
Journal:  Am J Transplant       Date:  2012-12-21       Impact factor: 8.086

6.  Medicare immunosuppressant coverage and access to kidney transplantation: a retrospective national cohort study.

Authors:  Vanessa Grubbs; Laura C Plantinga; Eric Vittinghoff; Ann M O'Hare; R Adams Dudley
Journal:  BMC Health Serv Res       Date:  2012-08-16       Impact factor: 2.655

7.  Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience.

Authors:  M Surendra; S B Raju; N Raju; S Chandragiri; K K Mukku; M S Uppin
Journal:  Indian J Nephrol       Date:  2016-09

8.  Low-dose Rituximab and Thymoglobulin Induction With Steroid-free Maintenance Immunosuppression and Protocol Biopsies Improves Long-term Patient and Graft Survival After Kidney Transplantation: Survival and Safety Outcomes in More Than 1100 Patients From a Single Center.

Authors:  Vivek Pathak; Devdas Madhavan; Kuppurajan Narayanasamy; Sampath Kumar; Vasanthan Ramalingam; Balasundaram Sengodagounder; Gabor Bodonyi-Kovacs
Journal:  Transplant Direct       Date:  2019-07-25

9.  Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.

Authors:  A Osama Gaber; Rita R Alloway; Kenneth Bodziak; Bruce Kaplan; Suphamai Bunnapradist
Journal:  Transplantation       Date:  2013-07-27       Impact factor: 4.939

10.  Association of medication non-adherence with short-term allograft loss after the treatment of severe acute kidney transplant rejection.

Authors:  Ahmed Al-Sheyyab; Laura Binari; Mohammed Shwetar; Everly Ramos; Meghan E Kapp; Stefanie Bala; Nikita Wilson; Rachel C Forbes; J Harold Helderman; Khaled Abdel-Kader; Beatrice P Concepcion
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.